Opinion

Video

The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.

Video content above is prompted by the following:

  • Previously, I mentioned the benefits of Lp(a) testing, even in the absence of targeted Lp(a)-lowering therapies. Let’s explore that further. How might Lp(a) testing improve overall cardiovascular risk assessment?
  • How, if at all, might Lp(a) measurement influence the management of other risk factors?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
4 experts are featured in this series.
5 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo